Bayer drug shown to slow diabetic kidney disease

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 23, 2020 at 11:32 AM.

  1. #1 cafead, Oct 23, 2020 at 11:32 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,057
    Likes Received:
    3
    via Bayer's BAYGn.DE finerenone drug slowed the progression of diabetic kidney disease in a late stage clinical trial, underscoring the company's hopes for the drug to generate at least 1 billion euros ($1.2 billion) in annual sales.

    article source
     
    Quote

Reply to Thread